Skip to main content

Synaptic dysfunction in Neurodegenerative Diseases

SYNDEGEN

Start Date
End Date
Total Funding
€ 3 129 428
Funding Programme
European Countries Involved

Neurodegenerative diseases (NDDs) of aging are a growing burden on societies. Although studies on the degeneration of neurons have been a main focus of research, increasing evidence points to synapses as the site where Alzheimer’s disease (AD), Parkinson’s disease (PD) and Huntington’s disease (HD) begin. There is growing evidence that synapses are sites of early and aberrant protein misfolding, aggregation and spread in NDDs. A key problem in research on NDDs has been that the normal physiological roles at synapses of the aggregation-prone proteins (β- amyloid/amyloid precursor protein, tau, α-synuclein and huntingtin), which are linked pathologically and genetically to these diseases, are not known. Using cutting-edge technologies and multidisciplinary approaches the SYNDEGEN consortium aims to bring together leading experts in cell biology, synapse biology and imaging, stem cell biology and NDDs in Europe to determine the molecular and cellular mechanisms whereby synapses become dysfunctional in AD, PD and HD for the purpose of developing novel therapies. The goal of the consortium is to train talented young scientists in interdisciplinary, innovative and collaborative research aimed at the development of novel molecular based treatment strategies for these major diseases of aging. A gap in the training of students in these important diseases is that disease expertise and novel methods to study synapses are localized in isolated groups in different locations in the EU. Similar questions are being asked about the mechanisms of synaptic dysfunction in AD, PD and HD, but no one university or company has sufficiently broad knowledge and technical expertise required to study and develop therapies for synaptic dysfunction in these disorders. This training programme will be implemented in 6 academic centres and 2 SMEs representing a comprehensive, highly interactive and multidisciplinary partnership.

Project partners

Deutsches Zentrum Fur Neurodegenerative Erkrankungen Ev
The Chancellor Masters And Scholarsof The University Of Cambridge
Ecole Polytechnique Federale De Lausanne
Umecrine Ab
Explora Nova Sarl
Universitaetsmedizin Goettingen - Georg-August-Universitaet Goettingen - Stiftung Oeffentlichen Rechts
Centre National De La Recherche Scientifique Cnrs
H. Lundbeck As
Neuroproof Gmbh
Skane Lans Landsting
Swedish Parkinson Foundation
Universitaet Ulm
Umea Universitet
Lunds Universitet

 
Acknowledgement
Alzheimer Europe's database on research projects was developed as part of the 2020 Work Plan which received funding under an operating grant from the European Union’s Health Programme (2014–2020).